Osteopore Partners with RxCell for Regenerative Medicine
Company Announcements

Osteopore Partners with RxCell for Regenerative Medicine

Osteopore Ltd. (AU:OSX) has released an update.

Osteopore Ltd., a leader in 3D-printed bioresorbable implants, has announced a collaboration with RxCell Inc., a U.S. biotech company specializing in induced pluripotent stem cell (iPSC) technology. This partnership marks Osteopore’s expansion into the burgeoning scaffold-based cell therapy market, promising to advance regenerative medicine and improve patient recovery outcomes. The deal includes the formation of a Technology Advisory Committee to explore co-development and resource sharing, with the potential for seeking third-party funding.

For further insights into AU:OSX stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App